Aerin Medical develops therapeutic devices that utilize minimally invasive techniques to enhance nasal airflow and improve respiratory function. The company addresses issues related to nasal obstruction, providing measurable benefits in breathing efficiency and overall quality of life for patients.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.